Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit Soubeyrand

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Expert Review of Vaccines|June 28, 2016
Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health toolsEmmanuel Vidor, Benoit Soubeyrand
Nature|June 7, 2002
Microbial evolution: antitoxin vaccines and pathogen virulenceBenoit Soubeyrand, Stanley A Plotkin
Evolution, Medicine, and Public Health|August 29, 2022
Can vaccines control bacterial virulence and pathogenicity? <i>Bordetella pertussis</i>: the advantage of fitness over virulenceNicole Guiso, Benoit Soubeyrand, Denis Macina
Human Vaccines & Immunotherapeutics|November 28, 2018
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of ageHervé Haas, Patrick Richard, Cécile Eymin, et al.
Human Vaccines|March 29, 2011
Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of ageVincent Gajdos, Benoit Soubeyrand, Emmanuel Vidor, et al.
Advances in Therapy|February 26, 2010
Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccinePhilippe Reinert, Sandro Cinquetti, Benoit Soubeyrand, et al.
Patient Preference and Adherence|November 26, 2015
What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?Andrew J Lloyd, Beenish Nafees, Eddy Ziani, et al.
Human Vaccines & Immunotherapeutics|October 4, 2012
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuriesHenri Laurichesse, Ulrich Zimmermann, Florence Galtier, et al.
Human Vaccines|September 25, 2010
Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination historySylvie Larnaudie, Nicole Guiso, Charles Baptiste, et al.
European Journal of Pediatrics|May 13, 2010
Hospitalization of newborns and young infants for chickenpox in FranceAurélie Lécuyer, Corinne Levy, Joel Gaudelus, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Expert Review of Vaccines|June 28, 2016
Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health toolsEmmanuel Vidor, Benoit Soubeyrand
Nature|June 7, 2002
Microbial evolution: antitoxin vaccines and pathogen virulenceBenoit Soubeyrand, Stanley A Plotkin
Evolution, Medicine, and Public Health|August 29, 2022
Can vaccines control bacterial virulence and pathogenicity? <i>Bordetella pertussis</i>: the advantage of fitness over virulenceNicole Guiso, Benoit Soubeyrand, Denis Macina
Human Vaccines & Immunotherapeutics|November 28, 2018
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of ageHervé Haas, Patrick Richard, Cécile Eymin, et al.
Human Vaccines|March 29, 2011
Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of ageVincent Gajdos, Benoit Soubeyrand, Emmanuel Vidor, et al.
Advances in Therapy|February 26, 2010
Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccinePhilippe Reinert, Sandro Cinquetti, Benoit Soubeyrand, et al.
Patient Preference and Adherence|November 26, 2015
What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution?Andrew J Lloyd, Beenish Nafees, Eddy Ziani, et al.
Human Vaccines & Immunotherapeutics|October 4, 2012
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuriesHenri Laurichesse, Ulrich Zimmermann, Florence Galtier, et al.
Human Vaccines|September 25, 2010
Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination historySylvie Larnaudie, Nicole Guiso, Charles Baptiste, et al.
European Journal of Pediatrics|May 13, 2010
Hospitalization of newborns and young infants for chickenpox in FranceAurélie Lécuyer, Corinne Levy, Joel Gaudelus, et al.
Pageof 2